Academic Journals Database
Disseminating quality controlled scientific knowledge

The diagnosis of anthracycline-induced cardiac damage and heart failure

ADD TO MY LIST
 
Author(s): Jarosław Dudka | Franciszek Burdan | Agnieszka Korga | Katarzyna Dyndor | Iwona Syroka | Justyna Zięba | Dorota Lewkowicz | Agnieszka Korobowicz-Markiewicz

Journal: Postępy Higieny i Medycyny Doświadczalnej
ISSN 0032-5449

Volume: 63;
Issue: 835515;
Start page: 225;
Date: 2009;
Original page

Keywords: antineoplastic chemotherapy | Anthracyclines | cardiotoxicity

ABSTRACT
Routine examinations during chemotherapy containing anthracyclines evaluate heart function before treatment and monitor cardiotoxic effects during and after therapy. A number of methods are useful in cardiac assessment, including electrocardiography, radiology techniques (RTG, CT, MRI, PET-CT, PET-MRI), echocardiography, radioisotope imaging techniques (scyntygraphy, MUGA, PET), and ultra-structure evaluation in biopsy samples. Nevertheless, there is a continuous need for new methods to predict future damage at the initial stages of cardiac changes. In recent years the therapeutic usefulness of biochemical blood parameters in anthracycline-treated patients has been assessed. The levels of cardiac troponines (cTnI, cTnT), natriuretic peptides (ANP, BNP), and endothelin 1 have been included in the studies. Heart-type fatty acid binding protein (H-FABP) is another promising factor showing cardiomyocytic impairment. However, the clinical use of biochemical parameters in diagnosing anthracycline-related cardiotoxicity is still a controversial issue.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?